IM156
Phase 1Small molecule
IM156 is one of 12 small molecule programs targeting Pancreas Cancer. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Pancreas Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Beyfortus
BeiGenePhase 2
Neoadjuvant Chemotherapy
JJapan Clinical Oncology Group
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Leukine
SanofiPhase 1
SX-682
SSyntrix Biosystems, Inc.
Phase 2
Folfirinox
PPhanes Therapeutics
Phase 2
Cyclophosphamide Pill
KKiromic BioPharma Inc.
Phase 2
IM156
IImmunoMet Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IM156. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- IImmunoMet Therapeutics, Inc.